Brief Report: Real-World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C-Mutated NSCLC

Introduction: The KRAS G12C inhibitor sotorasib was approved for treating advanced NSCLC in the second line or later on the basis of the CodeBreaK100 trial. Nevertheless, data on the real-world efficacy and safety of sotorasib, and to its optimal dose, remain limited. Methods: Patients treated with...

Full description

Bibliographic Details
Published in:	JTO Clinical and Research Reports
Main Authors:	Katherine I. Zhou, MD, PhD, Chenyu Lin, MD, Chin-Lin Tseng, MPH, Nithya Ramnath, MBBS, Jonathan E. Dowell, MD, Michael J. Kelley, MD
Format:	Article
Language:	English
Published:	Elsevier 2024-05-01
Subjects:	Sotorasib KRAS KRAS G12C Non-small cell lung cancer (NSCLC) Real-world Dose reduction
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364324000407

Similar Items

Mixed response to the first‐line treatment of KRAS G12C inhibitor, sotorasib, in non‐small cell lung cancer: A brief report
by: Jiao Yang, et al.
Published: (2024-06-01)

Sotorasib resistance triggers epithelial-mesenchymal transition and activates AKT and P38-mediated signaling
by: Raquel Arantes Megid, et al.
Published: (2025-01-01)

Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report
by: Alessandro Inno, et al.
Published: (2023-06-01)

Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysisResearch in context
by: Sophie M. Ernst, et al.
Published: (2024-04-01)

KRAS-mutated non-small cell lung cancer: new therapy strategies
by: K. K. Laktionov, et al.
Published: (2024-05-01)

Synergistic anticancer effects of camptothecin and sotorasib in KRAS-mutated pancreatic ductal adenocarcinoma
by: Prasanna Srinivasan Ramalingam, et al.
Published: (2025-07-01)

Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report
by: Parvin Begum, MBChB.(Hons), et al.
Published: (2021-09-01)

KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential
by: Metin Eser, et al.
Published: (2024-11-01)

The First Case Report of Effective Treatment With Sotorasib for Metastatic Atypical Lung Carcinoid Harboring KRAS G12C Mutation and Aggressive Disseminated Lung Metastasis: A Case Report
by: Masafumi Saiki, MD, et al.
Published: (2024-01-01)

Sotorasib in KRAS p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a KRAS Inhibitor in Symptomatic Brain Metastases
by: Jonas Frederik Schmidt, et al.
Published: (2024-09-01)

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
by: Sahar F. Bannoura, et al.
Published: (2022-11-01)

De Novo SCLC Transformation From KRAS G12C-Mutated Lung Adenocarcinoma With Excellent Response to Sotorasib: A Case Report
by: Takanori Ito, MD, et al.
Published: (2023-05-01)

CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
by: Brazel D, et al.
Published: (2023-04-01)

Sotorasib Is Not Effective in a KRAS‐Mutated Patient With Brain Metastases From Lung Adenocarcinoma due to Multiple Gene Co‐Mutations
by: Takayuki Suetsugu, et al.
Published: (2025-05-01)

Targeting USP47 enhances the efficacy of KRAS inhibitor in KRASG12C mutated non-small cell lung cancer by controlling deubiquitination of c-Myc
by: Hyungkyung Shin, et al.
Published: (2025-05-01)

Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With Immunotherapy
by: Lova Sun, MD, MSCE, et al.
Published: (2025-01-01)

A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations
by: Jonathan W. Riess, MD, MS, et al.
Published: (2025-06-01)

Sex-Related Safety Signals of Sotorasib in Non-Small Cell Lung Cancer: A Real-World, Pharmacovigilance Study from the EudraVigilance Database
by: Desirèe Speranza, et al.
Published: (2025-10-01)

Tolerability of sotorasib for KRAS positive lung adenocarcinoma patient with pre-existing interstitial pneumonia; A case report
by: Kohei Okada, et al.
Published: (2023-01-01)

Interaction Mechanisms of KRAS G12C Inhibitors (Sotorasib and Adagrasib) with Human Serum Albumin: Insights from Spectroscopic and Molecular Docking Studies
by: Junsong Qin, et al.
Published: (2025-08-01)

DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRASG12C-mutant cancer
by: Li-Wen Chiou, et al.
Published: (2023-06-01)

KRAS G12C inhibition enhances efficacy to conventional chemotherapy in KRAS-mutant NSCLC
by: Alessandro Tubita, et al.
Published: (2025-09-01)

Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis
by: Gu Xiaodong, et al.
Published: (2023-03-01)

Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
by: Satoru Miyazaki, et al.
Published: (2025-02-01)

Potential biomarkers uncovered by bioinformatics analysis in sotorasib resistant-pancreatic ductal adenocarcinoma
by: Prasanna Srinivasan Ramalingam, et al.
Published: (2023-06-01)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
by: Lixiu Peng, et al.
Published: (2023-01-01)

Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
by: Kathryn C. Arbour, MD, et al.
Published: (2022-01-01)

KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges
by: Judit Moldvay, et al.
Published: (2024-01-01)

A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer
by: Prakash Kulkarni, et al.
Published: (2023-10-01)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
by: Silvia Moreno, et al.
Published: (2021-04-01)

Study of the blood–brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases
by: Danming He, et al.
Published: (2026-06-01)

Prognostic Value of KRAS/TP53 Status for Overall Survival in First-Line Monoimmunotherapy and Chemoimmunotherapy Treated Patients With Nonsquamous NSCLC in the Netherlands: A Brief Report
by: Vincent D. de Jager, MD, et al.
Published: (2024-12-01)

Dual inhibition of GTP-bound KRAS and mTOR in lung adenocarcinoma and squamous cell carcinoma harboring KRAS G12C
by: Masaoki Ito, et al.
Published: (2025-05-01)

Real-World Evidence Study of Patients with <i>KRAS</i>-Mutated NSCLC in Finland
by: Anna Anttalainen, et al.
Published: (2024-05-01)

The efficacy of immunotherapy in non-small cell lung cancer with KRAS mutation: a systematic review and meta-analysis
by: Rui Zhao, et al.
Published: (2024-11-01)

KRAS mutated Non‐Small Lung Carcinoma: A Real World Context from the Indian subcontinent
by: Ullas Batra, et al.
Published: (2023-02-01)

Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC
by: Parneet K. Cheema, et al.
Published: (2023-07-01)

Early monitoring of plasma KRAS G12C with digital PCR predicts antitumor response to immunotherapy or sotorasib in advanced NSCLC: A brief report
by: Andrea De Giglio, et al.
Published: (2024-12-01)

The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy
by: Francis Proulx-Rocray, et al.
Published: (2023-01-01)

Targeting KRAS: The Elephant in the Room of Epithelial Cancers
by: Valeria Merz, et al.
Published: (2021-03-01)